Treatment with atorvastatin is associated with a better prognosis in chronic heart failure with systolic dysfunction: Results from The Daunia Heart Failure Registry

Netherlands Heart Journal

Volumn 21, Issue 9, 2013, Pages 408-416

  Correale, M ^a   Totaro, A ^a   Passero, T ^a   Abruzzese, S ^a   Musaico, F ^a   Ferraretti, A ^a   Ieva, R ^a   Di Biase, M ^a   Brunetti, N D ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Atorvastatin; Chronic heart failure; Echocardiography; Tissue Doppler imaging

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IVABRADINE;

AGED; ARTICLE; CONTROLLED STUDY; DEATH; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSPECTIVE STUDY; SIDE EFFECT; SYSTOLIC DYSFUNCTION; SYSTOLIC TIME INTERVAL; TISSUE DOPPLER IMAGING; TRANSTHORACIC ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 84883164366     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-013-0430-y     Document Type: Article

References (44)

1. Pai RG, Gill KS. Amplitudes, durations and timings of apically directed left ventricular myocardial velocities: I. Their normal pattern and coupling to ventricular filling and ejection. J Am Soc Echocardiogr. 1998;11:105-11.
2. Correale M, Totaro A, Ieva R, et al. Time intervals and myocardial performance index by tissue Doppler imaging. Intern Emerg Med. 2011;6:393-402.
3. Reant P, Dijos M, Donal E, Mignot A, Ritter P, Bordachar P, Dos Santos P, Leclercq C, Roudaut R, Habib G, Lafitte S. Systolic time intervals as simple echocardiographic parameters of left ventricular systolic performance: correlation with ejection fraction and longitudinal two-dimensional strain. Eur J Echocardiogr. 2010;11(10):834-44.
4. Cheng HM, Chuang SY, Hsu PF, et al. Systolic time intervals revisited: correlations with N-terminal pro-brain natriuretic peptide in a community population. Hear Vessel. 2005;20:256-63.
5. Dilaveris P, Giannopoulos G, Riga M, et al. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol. 2007;5:227-37.
6. Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and non-ischemic cardiomyopathy. J Am Coll Cardiol. 2008;5:415-26.
7. Levy WC. Observational studies of statins in systolic heart failure. Heart Fail Clin. 2008;4:201-8.
8. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopath-ic dilated cardiomyopathy. Circulation. 2003;108:839-43.
9. Wojnicz R, Wilczek K, Nowalany-Kozielska E, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol. 2006;97:899-904.
10. Sola S, Mir MQ, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47:332-7.
11. Yamada T, Node K, Mine T, et al. Long-term effects of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J. 2007;153:1055.e1-8.
12. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, et al. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit. 2009;15:MS12-23.
13. Krum H, Latini R, Maggioni AP, et al. Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol. 2007;119:48-53.
14. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004;93:1124-9.
15. Scirica BM, Morrow DA, Cannon CP, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006;47:2326-31.
16. Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007;115:576-83.
17. Horwich TB, MacLellan WR. Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother. 2007;8:3061-8.
18. Gürgün C, Ildizli M, Yavuzgil O, et al. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol. 2008;123:102-7.
19. Correale M, Brunetti ND, Totaro A, et al. Statin therapy blunts inflammatory activation and improves prognosis and left ventricular performance assessed by Tissue Doppler Imaging in subjects with chronic ischemic heart failure: results from the Daunia Heart Failure Registry. Clinics. 2011;66:777-84.
20. Yu CM, Chau E, Sanderson JE, et al. Tissue Doppler echocardio-graphic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation. 2002;105:438-45.
21. Haeck ML, Hoogslag GE, Rodrigo SF, et al. Treatment options in end-stage heart failure: where to go from here? Neth Heart J. 2012;20(4):167-75.
22. van der Wall EE. Are statins more effective in male patients? Neth Heart J. 2012;20(9):343-4.
23. Aronson D, Mutlak D, Lessick J, et al. Relation of statin therapy to risk of heart failure after acute myocardial infarction. Am J Cardiol. 2008;102:1706-10.
24. Correale M, Abruzzese S, Greco CA, Concilio M, Di Biase M, Brunetti ND. Statins in Heart Failure. Curr Vasc Pharmacol. 2012 Sep 20. in press.
25. Huan Loh P, Windram JD, Tin L, et al. The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality after the diagnosis of left ventricular systolic dysfunction. Am Heart J. 2007;153:537-44.
26. Sola S, Mir MQ, Rajagopalan S, et al. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail. 2005;11:607-12.
27. Kishi T, Yamada A, Okamatsu S, et al. Atorvastatin might improve ventricular electrostability and decelerate the deterioration of renal function in patients with heart failure and diabetes mellitus. J Cardiol. 2009;53:341-8.
28. Sankaranarayanan R, Maini S, James MA, et al. Do statins improve heart failure outcome in post-myocardial infarction patients with moderate to severe left ventricular dysfunction? Congest Heart Fail. 2010;16:181-6.
29. Cleland JGF, Coletta AP, Abdellah AT, et al. Clinical trials update from the American Heart Association 2007: corona, rethinq, mascot, Af-Chf, hart, master, poise and stem cell therapy. Eur J Heart Fail. 2008;10:102-8.
30. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231-9.
31. Zhang S, Zhang L, Sun A, et al. Efficacy of statin therapy in chronic systolic cardiac insufficiency: a meta-analysis. Eur J Intern Med. 2011;22:478-84.
32. Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2007;153:573-8.
33. Das MK, Zipes DP. Antiarrhythmic and non-antiarrhythmic drugs for sudden cardiac death prevention. J Cardiovasc Pharmacol. 2010;55:438-49.
34. Desai H, Aronow WS, Tsai FS, et al. Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implant-able cardioverter-defibrillator therapy. J Cardiovasc Pharmacol Ther. 2009;14:176-9.
35. Correale M, Totaro A, Ieva R, et al. Tissue Doppler imaging in coronary artery diseases and heart failure. Curr Cardiol Rev. 2012;8:43-53.
36. Qie L, Meng X, Wang Y, et al. Assessment of regional systolic and diastolic functions affected by atorvastatin in coronary artery disease using tissue Doppler imaging. Clin Cardiol. 2008;31:551-5.
37. Correale M, Totaro A, Greco CA, et al. Tissue Doppler time intervals predict the occurrence of rehospitalization in chronic heart failure: data from the daunia heart failure registry. Echocardiography. 2012;29:906-13.
38. Jarnert C, Mejhert M, Ring M, et al. Doppler tissue imaging in congestive heart failure patients due to diastolic or systolic dysfunction: a comparison with Doppler echocardiography and the atrio-ventricular plane displacement technique. Eur J Heart Fail. 2000;2:151-60.
39. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angio-tensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59:646-54.
40. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res. 2006;98:730-42.
41. Wang CY, Liao JK. Current advances in statin treatment: from molecular mechanisms to clinical practice. Arch Med Sci. 2007;3: S91-6.
42. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711-9.
43. Saijonmaa O, Nyman T, Stewen P, et al. Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. Am J Physiol Heart Circ Physiol. 2004;286:H2096-102.
44. Tousoulis D, Oikonomou E, Siasos G, Chrysohoou C, Zaromitidou M, Kioufis S, Maniatis K, Dilaveris P, Miliou A, Micaela S, Papavassiliou AG, Stefanadis C. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis 2013;227(2):367-72.